Search results
May 6, 2024 · ST. LOUIS, May 06, 2024--Geneoscopy, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening test, ColoSense.
6 days ago · The new screening tool is the first to use RNA biomarkers to detect the presence of colon cancer and advanced adenomas. The new RNA-based test is a non-invasive alternative to colonoscopy for adults ages 45 and older with an average risk of colon cancer.
Bethesda, MD (March 5, 2021) – The American College of Gastroenterology has issued updated evidence-based screening guidelines for colorectal cancer (CRC) in the March issue of The American Journal of Gastroenterology that recommend all average risk individuals begin screening at age 45.
6 days ago · The US Food and Drug Administration (FDA) has approved ColoSense (Geneoscopy, Inc), a multitarget stool RNA (mt-sRNA) test for colorectal cancer (CRC) screening in adults aged 45 or older who are ...
Mar 15, 2024 · In a study published this week in The New England Journal of Medicine, researchers found that a type of blood test known as a cell-free DNA blood-based test or cfDNA test was able to detect...
Dec 6, 2022 · Colonoscopy takes about 30 to 60 minutes and screening is generally repeated every 10 years if no abnormalities are found and you don't have an increased risk of colon cancer. The pros: Colonoscopy is one of the most sensitive tests currently available for colon cancer screening.
Mar 14, 2024 · The results of a clinical trial, published Wednesday, in The New England Journal of Medicine, show that the blood-based screening test detects 83% of people with colorectal cancer. If the...
